Devah Therapeutics
Devah Therapeutics specializes in repurposing proven pharmaceutical molecules, applying contemporary scientific approaches to address stress-related, metabolic, and neuropsychiatric conditions that lack effective treatments. By utilizing the FDA 505(b)(2) regulatory pathway, the company accelerates drug development, minimizes clinical risk, and explores new indications for molecules with established safety. Their focus is on restoring resilience and quality of life through therapies underpinned by mechanism-based science. The company's lead program is based on a chemistry estate with decades of safe use, targeting multiple indications through targeted modulation of neurobiological and metabolic pathways.
Industries
N/A
Products
A therapy under development utilizing a compound with a long history of safe use, repositioned for stress-related, neuropsychiatric, and metabolic indications such as PTSD, anxiety, perimenopausal vasomotor symptoms, and hyperuricemia/gout.
A therapy under development utilizing a compound with a long history of safe use, repositioned for stress-related, neuropsychiatric, and metabolic indications such as PTSD, anxiety, perimenopausal vasomotor symptoms, and hyperuricemia/gout.
Expertise Areas
- Drug repurposing
- Central nervous system therapeutic development
- Regulatory strategy (505(b)(2))
- Mechanism-based drug discovery
Key Technologies
- Phosphodiesterase inhibition
- HPA-axis modulation
- Neuro-molecular resilience analysis
Key People
Founder & Chief Executive Officer
Founder & Chief Executive Officer